EA038358B1 - Антитела к альфа-синуклеину и их применение - Google Patents

Антитела к альфа-синуклеину и их применение Download PDF

Info

Publication number
EA038358B1
EA038358B1 EA201892548A EA201892548A EA038358B1 EA 038358 B1 EA038358 B1 EA 038358B1 EA 201892548 A EA201892548 A EA 201892548A EA 201892548 A EA201892548 A EA 201892548A EA 038358 B1 EA038358 B1 EA 038358B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
ser
synuclein
antigen
seq
Prior art date
Application number
EA201892548A
Other languages
English (en)
Russian (ru)
Other versions
EA201892548A1 (ru
Inventor
Майкл Перкинтон
Дарен Шофилд
Лоррейн Ирвинг
Джордж Том
Original Assignee
Медиммун Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиммун Лимитед filed Critical Медиммун Лимитед
Publication of EA201892548A1 publication Critical patent/EA201892548A1/ru
Publication of EA038358B1 publication Critical patent/EA038358B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
EA201892548A 2016-06-02 2017-06-01 Антитела к альфа-синуклеину и их применение EA038358B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344746P 2016-06-02 2016-06-02
PCT/EP2017/063406 WO2017207739A1 (en) 2016-06-02 2017-06-01 Antibodies to alpha-synuclein and uses thereof

Publications (2)

Publication Number Publication Date
EA201892548A1 EA201892548A1 (ru) 2019-06-28
EA038358B1 true EA038358B1 (ru) 2021-08-13

Family

ID=59021492

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201892548A EA038358B1 (ru) 2016-06-02 2017-06-01 Антитела к альфа-синуклеину и их применение
EA202191380A EA202191380A1 (ru) 2016-06-02 2017-06-01 Антитела к альфа-синуклеину и их применение

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202191380A EA202191380A1 (ru) 2016-06-02 2017-06-01 Антитела к альфа-синуклеину и их применение

Country Status (38)

Country Link
US (5) US10160800B2 (enExample)
EP (2) EP4000632A1 (enExample)
JP (3) JP7078552B2 (enExample)
KR (1) KR102499438B1 (enExample)
CN (2) CN109475616B (enExample)
AR (1) AR108663A1 (enExample)
AU (2) AU2017272804B2 (enExample)
BR (1) BR112018074978A2 (enExample)
CA (1) CA3025987A1 (enExample)
CL (1) CL2018003438A1 (enExample)
CO (1) CO2018014010A2 (enExample)
CY (1) CY1124896T1 (enExample)
DK (1) DK3463435T3 (enExample)
EA (2) EA038358B1 (enExample)
EC (1) ECSP18096095A (enExample)
ES (1) ES2903402T3 (enExample)
GE (1) GEP20217253B (enExample)
HR (1) HRP20211935T1 (enExample)
HU (1) HUE057214T2 (enExample)
IL (1) IL263243A (enExample)
LT (1) LT3463435T (enExample)
MA (1) MA45125B1 (enExample)
MD (1) MD3463435T2 (enExample)
MX (1) MX393740B (enExample)
MY (1) MY188183A (enExample)
NZ (1) NZ748616A (enExample)
PE (2) PE20190440A1 (enExample)
PH (1) PH12018502538A1 (enExample)
PL (1) PL3463435T3 (enExample)
PT (1) PT3463435T (enExample)
RS (1) RS62682B1 (enExample)
SG (1) SG11201810420YA (enExample)
SI (1) SI3463435T1 (enExample)
SM (1) SMT202200008T1 (enExample)
TW (2) TW202309093A (enExample)
UA (1) UA124733C2 (enExample)
WO (1) WO2017207739A1 (enExample)
ZA (1) ZA201808582B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JP7217229B2 (ja) 2016-11-15 2023-02-02 ハー・ルンドベック・アクチエゼルスカベット シヌクレイノパチーの治療のための薬剤、使用および方法
ES3008133T3 (en) 2016-12-16 2025-03-21 H Lundbeck As Agents, uses and methods
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
WO2020079113A1 (en) * 2018-10-19 2020-04-23 Janssen Vaccines & Prevention B.V. Anti-synuclein antibodies
TWI734279B (zh) 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
CA3133909A1 (en) 2019-04-18 2020-10-22 Elpida TSIKA Novel molecules for therapy and diagnosis
CN110172098B (zh) * 2019-05-27 2023-03-10 长春工业大学 抗α-突触核蛋白的单克隆抗体及其应用
CA3150726A1 (en) 2019-09-20 2021-03-25 Jing Guo Anti-alpha-synuclein antibodies and methods of use thereof
KR102239512B1 (ko) * 2020-09-10 2021-04-12 서울대학교산학협력단 다중기능성 마이크로캡슐 조성물 및 그 제조방법
WO2022079297A1 (en) 2020-10-16 2022-04-21 Ac Immune Sa Antibodies binding to alpha-synuclein for therapy and diagnosis
CN112920274A (zh) * 2021-03-17 2021-06-08 江苏贝格尔生物医药有限公司 一种检测alpha-synuclein蛋白的鼠单克隆抗体及其应用
CN113912716B (zh) * 2021-12-15 2022-03-01 北京凯祥弘康生物科技有限公司 针对α-突触核蛋白抗原的抗体及其应用
AU2023417097A1 (en) 2022-12-29 2025-08-14 Astrazeneca Ab Compositions and methods for treating alpha-synucleinopathies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103472A2 (en) * 2007-02-23 2008-08-28 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2011104696A1 (en) * 2010-02-26 2011-09-01 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
WO2014132210A1 (en) * 2013-02-28 2014-09-04 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2015075011A1 (en) * 2013-11-21 2015-05-28 F. Hoffmann-La Roche Ag ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5198704B2 (ja) 2000-03-03 2013-05-15 メディミューン リミティド エオタキシンに対するヒト抗体及びそれらの使用
EP1328626B1 (en) 2000-05-26 2013-04-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
HUE035044T2 (en) 2003-05-19 2018-05-02 Prothena Biosciences Ltd Truncated fragments of alpha-synuclein in Lewy-body disease
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
CA2623841C (en) 2005-09-27 2019-03-12 National Research Council Of Canada Methods of identifying agents capable of tmem30a mediated transmigration across the blood brain barrier (bbb)
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP4934074B2 (ja) 2007-03-07 2012-05-16 株式会社アルファ スイッチ固定構造
LT2282758T (lt) 2008-04-29 2019-03-12 Bioarctic Ab Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams
PT2370466E (pt) 2008-12-19 2015-09-21 Univ Zuerich Autoanticorpos humanos anti-alfa-sinucleína
JP4654348B1 (ja) 2010-02-23 2011-03-16 多摩川精機株式会社 検出装置用巻線の正弦波巻線方法
AU2012272790B2 (en) 2011-06-23 2016-10-06 Biogen International Neuroscience Gmbh Anti-alpha synuclein binding molecules
EP3378535B1 (en) 2011-10-28 2023-01-04 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
HRP20210888T4 (hr) 2014-11-10 2024-12-06 Medimmune Limited Vezujuće molekule specifične za cd73 i njihova upotreba

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103472A2 (en) * 2007-02-23 2008-08-28 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2011104696A1 (en) * 2010-02-26 2011-09-01 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
WO2014132210A1 (en) * 2013-02-28 2014-09-04 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2015075011A1 (en) * 2013-11-21 2015-05-28 F. Hoffmann-La Roche Ag ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. GAMES, E. VALERA, B. SPENCER, E. ROCKENSTEIN, M. MANTE, A. ADAME, C. PATRICK, K. UBHI, S. NUBER, P. SACAYON, W. ZAGO, P. SEUBER: "Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models", THE JOURNAL OF NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, US, vol. 34, no. 28, 9 July 2014 (2014-07-09), US, pages 9441 - 9454, XP055322627, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.5314-13.2014 *
JUN SUNG LEE, SEUNG-JAE LEE: "Mechanism of Anti-α-Synuclein Immunotherapy", JOURNAL OF MOVEMENT DISORDERS, vol. 9, no. 1, 1 January 2016 (2016-01-01), pages 14 - 19, XP055399298, ISSN: 2005-940X, DOI: 10.14802/jmd.15059 *

Also Published As

Publication number Publication date
SI3463435T1 (sl) 2022-02-28
PL3463435T3 (pl) 2022-02-14
MY188183A (en) 2021-11-24
PE20190440A1 (es) 2019-03-27
KR20190013923A (ko) 2019-02-11
AU2017272804B2 (en) 2023-11-23
AU2024200601A1 (en) 2024-04-18
PT3463435T (pt) 2021-11-22
NZ748616A (en) 2025-08-29
MX393740B (es) 2025-03-24
EA201892548A1 (ru) 2019-06-28
WO2017207739A1 (en) 2017-12-07
IL263243A (en) 2018-12-31
TWI765890B (zh) 2022-06-01
US10889639B2 (en) 2021-01-12
JP7078552B2 (ja) 2022-05-31
MA45125B1 (fr) 2021-11-30
CN109475616A (zh) 2019-03-15
CA3025987A1 (en) 2017-12-07
CN116120445A (zh) 2023-05-16
PH12018502538A1 (en) 2019-04-08
AU2017272804A1 (en) 2018-12-13
US20230331830A1 (en) 2023-10-19
CN109475616B (zh) 2022-10-18
LT3463435T (lt) 2021-12-27
CO2018014010A2 (es) 2019-01-18
EP4000632A1 (en) 2022-05-25
PE20250392A1 (es) 2025-02-11
ES2903402T3 (es) 2022-04-01
CY1124896T1 (el) 2023-01-05
JP2022110117A (ja) 2022-07-28
ECSP18096095A (es) 2019-01-31
US20190276522A1 (en) 2019-09-12
US20250263477A1 (en) 2025-08-21
JP2019527194A (ja) 2019-09-26
US10160800B2 (en) 2018-12-25
HRP20211935T1 (hr) 2022-03-18
US11560424B2 (en) 2023-01-24
SMT202200008T1 (it) 2022-03-21
UA124733C2 (uk) 2021-11-10
RS62682B1 (sr) 2021-12-31
US20180002411A1 (en) 2018-01-04
TW202309093A (zh) 2023-03-01
CL2018003438A1 (es) 2019-03-22
MA45125A (fr) 2021-06-02
MD3463435T2 (ro) 2022-03-31
EP3463435A1 (en) 2019-04-10
GEP20217253B (en) 2021-05-13
KR102499438B1 (ko) 2023-02-14
MX2018014456A (es) 2019-08-12
TW201802119A (zh) 2018-01-16
SG11201810420YA (en) 2018-12-28
EP3463435B1 (en) 2021-10-13
US20210179698A1 (en) 2021-06-17
HUE057214T2 (hu) 2022-04-28
AR108663A1 (es) 2018-09-12
JP2024123247A (ja) 2024-09-10
DK3463435T3 (da) 2021-11-22
ZA201808582B (en) 2021-08-25
BR112018074978A2 (pt) 2019-03-12
EA202191380A1 (ru) 2021-08-26

Similar Documents

Publication Publication Date Title
US11560424B2 (en) Antibodies to alpha-synuclein and uses thereof
JP7138322B2 (ja) シヌクレイノパチーの治療のための薬剤、使用および方法
JP7217229B2 (ja) シヌクレイノパチーの治療のための薬剤、使用および方法
JP6952827B2 (ja) 血液脳関門輸送分子およびそれらの使用
JP7730162B2 (ja) 配列類似性19、メンバーa5抗体を有する抗ファミリー及びその使用方法
JP2022515960A (ja) 抗配列類似性19を持つファミリー、メンバーa5抗体及びその使用方法
HK40072606A (en) Antibodies to alpha-synuclein and uses thereof
HK40007492B (en) Antibodies to alpha-synuclein and uses thereof
HK40005896B (zh) 针对α-突触核蛋白的抗体及其用途
HK40005896A (en) Antibodies to alpha-synuclein and uses thereof
HK1254358B (en) Agents, uses and methods for the treatment of synucleinopathy